| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI) |
| 19 Aug 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on February 17, 2026, Mereo BioPharma Group plc (the “Company”) received a written notice (the “First Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) in... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) |
| 11 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) |
| 14 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 14, 2026, Mereo BioPharma Group plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”), and all resolutions were passed as proposed. Of the ordinary shares entitled to vote, there were 436,766,255 ord... |
| 12 May 2026 |
8-K: Completion of Acquisition or Disposition of Assets
London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026... |
| 27 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 26, 2026, Dr. Annalisa Jenkins informed Mereo BioPharma plc. (the “Company”) that she will not stand for re-election as a Director of the Board of Directors (the “Board”) of the Company at the Company’s 2026 annual general meeti... |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing |
| 17 Feb 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On February 17, 2026, Mereo BioPharma Group plc (the “Company”) received a letter (the “Notification Letter”) from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its American D... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential path forward for the program |
| 29 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 |
| 10 Jul 2025 |
8-K: Other Events
On July 9, 2025, Mereo BioPharma Group plc (“Mereo” or the “Company”) and Ultragenyx Pharmaceutical Inc. (“Ultragenyx”) announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in... |
| 14 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 13, 2025, Mereo BioPharma Group plc (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “AGM”), and all resolutions were passed as proposed (except for Resolution 6, as further described below). Of the ordina... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) |
| 26 Mar 2025 |
8-K: Results of Operations and Financial Condition
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 |
| 12 Nov 2024 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
Setrusumab receives Breakthrough Therapy designation from the FDA |
| 13 Aug 2024 |
8-K: Results of Operations and Financial Condition
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled |
Loading...